{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T02:22:57Z","timestamp":1780971777790,"version":"3.54.1"},"reference-count":17,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Cl\u00ednica Espa\u00f1ola (English Edition)"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.rceng.2025.02.006","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T19:34:31Z","timestamp":1740080071000},"page":"204-210","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["VERICIDuAT: Real-life study of vericiguat in patients with heart failure with reduced ejection fraction"],"prefix":"10.1016","volume":"225","author":[{"given":"S.","family":"Russo Botero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ripoll Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"F\u00e1cila Rubio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Lamilla \u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Montagud Balaguer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Garc\u00eda Escriv\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Chover Sierra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1.","family":"S\u00e1nchez Montagud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"P\u00e9rez Silvestre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.rceng.2025.02.006_bib0005","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1161\/CIR.0000000000000659","article-title":"Heart disease and stroke statistics \u2014 2019 update: a report from the American Heart Association","volume":"139","author":"Benjamin","year":"2019","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.rceng.2025.02.006_bib0010","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.recesp.2014.11.009","article-title":"Acute heart failure: epidemiology, risk factors, and prevention","volume":"68","author":"Farmakis","year":"2015","journal-title":"Rev Esp Cardiol (English Edition)."},{"issue":"8","key":"10.1016\/j.rceng.2025.02.006_bib0015","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.recesp.2013.12.016","article-title":"Health care and nonhealth care costs in the treatment of patients with symptomatic chronic heart failure in Spain","volume":"67","author":"Delgado","year":"2014","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"10.1016\/j.rceng.2025.02.006_bib0020","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.jacc.2018.11.049","article-title":"Clinical course of patients with worsening heart failure with reduced ejection fraction","volume":"73","author":"Butler","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.rceng.2025.02.006_bib0025","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002606","article-title":"Medication adherence interventions improve heart failure mortality and readmission rates: systematic review and meta-analysis of controlled trials","volume":"5","author":"Ruppar","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.rceng.2025.02.006_bib0030","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1002\/ejhf.1655","article-title":"Heart failure treatment and the art of medical decision making","volume":"21","author":"McAlister","year":"2019","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"10.1016\/j.rceng.2025.02.006_bib0035","doi-asserted-by":"crossref","first-page":"523.e1","DOI":"10.1016\/j.recesp.2021.11.027","article-title":"Gu\u00eda ESC 2021 sobre el diagn\u00f3stico y tratamiento de la insuficiencia card\u00edaca aguda y cr\u00f3nica","volume":"75","author":"McDonagh","year":"2022","journal-title":"Rev Esp Cardiol"},{"key":"10.1016\/j.rceng.2025.02.006_bib0040","unstructured":"Ficha t\u00e9cnica de vericiguat. Primera publicaci\u00f3n 27 Jul 2021. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/verquvo."},{"issue":"B","key":"10.1016\/j.rceng.2025.02.006_bib0045","first-page":"8","article-title":"Papel del vericiguat en la etiopatogenia global de la insuficiencia cardiaca con fracci\u00f3n de eyecci\u00f3n reducida. Posicionamiento actual","volume":"22","author":"Garc\u00eda-Quintana","year":"2022","journal-title":"Rev Esp Cardiol Supl."},{"key":"10.1016\/j.rceng.2025.02.006_bib0050","doi-asserted-by":"crossref","first-page":"5146","DOI":"10.1021\/acs.jmedchem.7b00449","article-title":"Discovery of the soluble guanylate cyclase stimulator vericiguat (BAY 1021189) for the treatment of chronic heart failure","volume":"60","author":"Follmann","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.rceng.2025.02.006_bib0055","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1001\/jama.2015.15734","article-title":"Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: the SOCRATES-REDUCED randomized trial","volume":"314","author":"Gheorghiade","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.rceng.2025.02.006_bib0060","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rceng.2025.02.006_bib0065","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jchf.2017.08.013","article-title":"A multicenter, randomized, double-blind, placebo-controlled trial of the efficacy and safety of the oral soluble guanylate cyclase stimulator: the VICTORIA trial","volume":"6","author":"Armstrong","year":"2018","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.rceng.2025.02.006_bib0070","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1002\/ejhf.1664","article-title":"Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial","volume":"21","author":"Pieske","year":"2019","journal-title":"Eur J Heart Fail"},{"issue":"20","key":"10.1016\/j.rceng.2025.02.006_bib0075","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N Engl J Med."},{"key":"10.1016\/j.rceng.2025.02.006_bib0080","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.rce.2021.12.005","article-title":"Vericiguat en insuficiencia card\u00edaca: de la evidencia cient\u00edfica a la pr\u00e1ctica cl\u00ednica","volume":"222","author":"Gonz\u00e1lez-Juanatey","year":"2022","journal-title":"Rev Cl\u00edn Esp"},{"key":"10.1016\/j.rceng.2025.02.006_bib0085","doi-asserted-by":"crossref","DOI":"10.1002\/ehf2.15032","article-title":"Clinical profile, associated events and safety of vericiguat in a real-world cohort: the VERITA study","author":"Galv\u00e1n Ruiz","year":"2024","journal-title":"ESC Heart Fail"}],"container-title":["Revista Cl\u00ednica Espa\u00f1ola (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2254887425000268?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2254887425000268?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T08:14:40Z","timestamp":1744532080000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2254887425000268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S2254887425000268"],"URL":"https:\/\/doi.org\/10.1016\/j.rceng.2025.02.006","relation":{},"ISSN":["2254-8874"],"issn-type":[{"value":"2254-8874","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"VERICIDuAT: Real-life study of vericiguat in patients with heart failure with reduced ejection fraction","name":"articletitle","label":"Article Title"},{"value":"Revista Cl\u00ednica Espa\u00f1ola (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rceng.2025.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.rce.2024.11.005","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Espa\u00f1a, S.L.U. and Sociedad Espa\u00f1ola de Medicina Interna (SEMI). All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}